MVP: Dermatological Care
Most applicable medical specialty(s):
Dermatology, non-physician practitioners, nurse practitioner, physician assistants
The Dermatological Care MVP focuses on the clinical theme of providing treatment and management of dermatologic care.
Quality
To fulfill quality requirements:
- You must select 4 quality measures from the list below
(exception for clinicians in a small practice – see # 3 below) - At least 1 measure must be an outcome measure
- If no outcome measures are available, you may report a high priority measure.
- If you are part of a small practice (i.e., 15 or fewer clinicians) reporting quality measures through Medicare Part B claims, you don’t need to report additional measures beyond the Medicare Part B claims measures available in this MVP. Reporting all of the Medicare Part B claims measures in this MVP will fulfill your quality reporting requirements.
- You must collect data for each measure for the 12-month performance period of the associated performance year (e.g., January 1, 2025 – December 31, 2025).
TIP: For small practices (participating at the individual, group or subgroup level) reporting Medicare Part B claims measures: To meet data completeness requirements, you’ll need to start reporting the Medicare Part B claims measures in your selected MVP in January 2025, prior to the MVP registration period.
TIP: Make sure that you select measures that are appropriate to your patient population. Measures that don’t meet case minimum or data completeness criteria will earn zero points.
Quality Measures (MVP ID: M1421)
| ID | Title | Specs |
|---|---|---|
| 130 | Documentation of Current Medications in the Medical Record | Details |
| 176 | Tuberculosis Screening Prior to First Course of Biologic and/or Immune Response Modifier Therapy | Details |
| 226 | Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention | Details |
| 397 | Melanoma Reporting | Details |
| 410 | Psoriasis: Clinical Response to Systemic Medications | Details |
| 440 | Skin Cancer: Biopsy Reporting Time – Pathologist to Clinician | Details |
| 485 | Psoriasis- Improvement in Patient-Reported Itch Severity | Details |
| 486 | Dermatitis – Improvement in Patient-Reported Itch Severity | Details |
| 487 | Screening for Social Drivers of Health | Details |
| 503 | Gains in Patient Activation Measure (PAM) Scores at 12 Months | Details |
| 509 | Melanoma: Tracking and Evaluation of Recurrence | Details |
| AAD6 | Skin Cancer: Biopsy Reporting Time – Clinician to Patient | Details |
| AAD8 | Chronic Skin Conditions: Patient Reported Quality-of-Life | Details |
| AAD12 | Melanoma: – Appropriate Surgical Margins | Details |
| AAD16 | Avoidance of Post-operative Systemic Antibiotics for Office-based Closures and Reconstruction After Skin Cancer Procedures | Details |
| AAD17 | Continuation of Anticoagulation Therapy in the Office-based Setting for Closure and Reconstruction After Skin Cancer Resection Procedures | Details |
| AAD18 | Avoidance of Opioid Prescriptions for Closure and Reconstruction After Skin Cancer Resection | Details |
Improvement Activities
To fulfill improvement activity requirements:
1. You must report 1 improvement activity from the list below.
Beginning in 2025, improvement activities don’t have assigned weights.
Improvement Activities (MVP ID: M1421)
| ID | Title |
|---|---|
| IA_AHE_1 | Enhance Engagement of Medicaid and Other Underserved Populations |
| IA_AHE_6 | Provide Education Opportunities for New Clinicians |
| IA_BE_4 | Engagement of patients through implementation of improvements in patient portal |
| IA_BE_6 | Regularly Assess Patient Experience of Care and Follow Up on Findings |
| IA_BE_15 | Engagement of Patients, Family, and Caregivers in Developing a Plan of Care |
| IA_EPA_2 | Use of telehealth services that expand practice access |
| IA_PM_26 | Vaccine Achievement for Practice Staff: COVID-19, Influenza, and Hepatitis B |
| IA_MVP | Practice-Wide Quality Improvement in MIPS Value Pathways |
| IA_PCMH | Electronic submission of Patient Centered Medical Home accreditation |
| IA_PM_16 | Implementation of medication management practice improvements |
| IA_PSPA_8 | Use of Patient Safety Tools |
Cost
Important information to consider:
- You don’t have to submit any data for this performance category. We’ll use Medicare claims data to
calculate your cost measure performance.
You don’t select cost measures during MVP registration. CMS will calculate your performance
on all the cost measures included in the MVP based on available Medicare claims data. - You’ll only be scored on the cost measures in this MVP for which you meet or exceed the established
case minimum.
Cost Measures (MVP ID: M1421)
| ID | Title | Specs |
|---|---|---|
| COST_MR_1 | Melanoma Resection | Details |
Foundational Layer – Promoting Interoperability
To fulfill Promoting Interoperability requirements:
- Submit the required Promoting Interoperability measures (the same as under traditional MIPS) listed below. Bonus points are available for reporting measures that aren’t required.
- If you’re reporting as a subgroup, you’ll submit your affiliated group’s data for the Promoting Interoperability performance category.
- Review if you qualify for automatic reweighting of the Promoting Interoperability performance category based on your clinician type, special status, or an approved Promoting Interoperability Performance Category Hardship Exception Application.
Special Status for Automatic Reweighting:
- Ambulatory Surgical Center (ASC)-based
- Hospital-based
- Non-patient facing
- Small practice
Promoting Interoperability Performance Category Hardship Exception Qualifications:
- Decertified EHR technology
- Insufficient internet connectivity
- Experience extreme and uncontrollable circumstances (e.g., disaster, practice closure, severe financial distress, vendor issues)
- Lack control over availability of CEHRT (Certified Electronic Health Record Technology)
Note: Promoting Interoperability requirements are the same in MVPs as they are in traditional MIPS. Learn more about Promoting Interoperability requirements.
| ID | Title |
|---|---|
| PI_EP_1 | e-Prescribing |
| PI_EP_2 | Query of the Prescription Drug Monitoring Program (PDMP) |
| PI_EP_2_EX_1 | Query of the Prescription Drug Monitoring Program (PDMP) |
| PI_EP_2_EX_2 | Query of the Prescription Drug Monitoring Program (PDMP) Exclusion |
| PI_HIE_1 | Support Electronic Referral Loops By Sending Health Information |
| PI_HIE_4 | Support Electronic Referral Loops By Receiving and Reconciling Health Information |
| PI_HIE_5 | Health Information Exchange (HIE) Bi-Directional Exchange |
| PI_HIE_6 | Enabling Exchange Under TEFCA |
| PI_INFBLO_1 | Actions to Limit or Restrict the Compatibility of CEHRT |
| PI_LVITC_2 | Support Electronic Referral Loops By Receiving and Reconciling Health Information Exclusion |
| PI_LVOTC_1 | Support Electronic Referral Loops By Sending Health Information Exclusion |
| PI_LVPP_1 | e-Prescribing Exclusion |
| PI_ONCACB_1 | ONC-ACB Surveillance Attestation |
| PI_ONCDIR_1 | ONC Direct Review Attestation |
| PI_PEA_1 | Provide Patients Electronic Access to Their Health Information |
| PI_PHCDRR_1 | Immunization Registry Reporting |
| PI_PHCDRR_1_EX_1 | Immunization Registry Reporting Exclusion |
| PI_PHCDRR_1_EX_2 | Immunization Registry Reporting Exclusion |
| PI_PHCDRR_1_EX_3 | Immunization Registry Reporting Exclusion |
| PI_PHCDRR_1_PRE | Immunization Registry Reporting Active Engagement Level 1 |
| PI_PHCDRR_1_PROD | Immunization Registry Reporting Active Engagement Level 2 |
| PI_PHCDRR_2 | Syndromic Surveillance Reporting |
| PI_PHCDRR_2_PRE | Syndromic Surveillance Reporting Active Engagement Level 1 |
| PI_PHCDRR_2_PROD | Syndromic Surveillance Reporting Active Engagement Level 2 |
| PI_PHCDRR_3 | Electronic Case Reporting |
| PI_PHCDRR_3_EX_1 | Electronic Case Reporting Exclusion |
| PI_PHCDRR_3_EX_2 | Electronic Case Reporting Exclusion |
| PI_PHCDRR_3_EX_3 | Electronic Case Reporting Exclusion |
| PI_PHCDRR_3_PRE | Electronic Case Reporting Active Engagement Level 1 |
| PI_PHCDRR_3_PROD | Electronic Case Reporting Active Engagement Level 2 |
| PI_PHCDRR_4 | Public Health Registry Reporting |
| PI_PHCDRR_4_PRE | Public Health Registry Reporting Active Engagement Level 1 |
| PI_PHCDRR_4_PROD | Public Health Registry Reporting Active Engagement Level 2 |
| PI_PHCDRR_5 | Clinical Data Registry Reporting |
| PI_PHCDRR_5_PRE | Clinical Data Registry Reporting Active Engagement Level 1 |
| PI_PHCDRR_5_PROD | Clinical Data Registry Reporting Active Engagement Level 2 |
| PI_PPHI_1 | Security Risk Analysis |
| PI_PPHI_2 | SAFER Guides High Priority Practices Guide |
Foundational Layer – Population Health
- You won’t be required to select a population health measure during registration. This is different from the 2024 MVP registration process requiring you to select a population health measure. You don’t have to submit any data for this measure, we will calculate all available population health measures for you, using administrative claims data.
- This measure will be excluded if you can’t be scored on either (the measure doesn’t have a benchmark or you don’t meet the case minimum).
- Population health isn’t a new performance category. The population health measures within the MVP will be scored as part of the quality performance category provided you meet the case minimum.
- Subgroups will be evaluated at the affiliated group level.
Improvement Activities (All MVPs)